Abstract
Background Preserved cognitive health with ageing is a public health imperative. Vitamin D deficiency is associated with poor cognition, but it is unclear whether supplementation would provide benefit, particularly in individuals with mild/moderate deficiencies which do not have other clinical risks. The objective of this study was to establish the impact of daily vitamin D supplementation on cognition in older adults with mild to moderate vitamin D deficiency.
Methods and Findings Two-arm parallel 24-month randomised controlled trial, with Vitamin D supplementation compared with a placebo. This was a remote trial, completed from home involving 620 adults 50 years or older with mild to moderate vitamin D deficiency and early cognitive impairment. The primary outcome was executive function measured through Trail making B and other secondary measures of cognition, function and wellbeing.
Vitamin D supplementation conferred no significant benefit to executive function compared to placebo at follow-up on the primary outcome (between-group difference: 5770, 95% CI: -2189 to 13730) or cognition, function, or wellbeing. Secondary analyses in defined subgroups and a per-protocol analysis also showed no significant impact on any outcome measures.
Conclusions Vitamin D supplementation produced no measurable improvement in cognitive outcomes in older adults with mild to moderate vitamin D deficiency. The remote trial methodology provides an innovative approach to large-scale trials.
Trial Registration ISRCTN79265514 https://www.isrctn.com/ISRCTN79265514
Competing Interest Statement
CB has received consulting fees from Acadia pharmaceutical company, AARP, Addex pharmaceutical company, Eli Lily, Enterin pharmaceutical company, GWPharm, H.Lundbeck pharmaceutical company, Novartis pharmaceutical company, Janssen Pharmaceuticals, Johnson and Johnson pharmaceuticals, Novo Nordisk pharmaceutical comapny, Orion Corp pharmaceutical company, Otsuka America Pharm Inc, Sunovion Pharm. Inc, Suven pharmaceutical company, Roche pharmaceutical company, Biogen pharmaceutical company, Synexus clinical research organization and tauX pharmaceutical company and research funding from Synexus clinical research organization, Roche pharmaceutical company, Novo Nordisk pharmaceutical company and Novartis pharmaceutical company. AC discloses financial relationships with Suven and Janssen pharmaceutical companies for consultancy work
Clinical Trial
ISRCTN79265514
Funding Statement
This work was funded by the Jon Moulton Charitable Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Wales Research Ethics Committee 3 of the UK Health Research Authority gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
